circRNA basic information
circBase ID: -
Name: hsa_circ_MYLK
Synonym: circMYLK
Host Gene: MYLK
Genomic location(hg19): -
Genomic location(hg38): -
Subcellular localization: not tested
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
0005595
MONDO name: laryngeal squamous cell carcinoma
Disease details: laryngeal squamous cell carcinoma
Disease DO ID:
2876
Disease MeSH ID:
-
Disease NCIt ID:
C4044
Disease ICD11 ID:
-
Disease OMIM ID:
-
Species: Human
Species details: Homo sapiens
Tissue specimen:

LSCC tissues; matched adjacent non-tumorous tissues

Cell lines:

AMC-HN-8; Tu-177; 16HBE

In vivo animal model:

-

circRNA-disease information
Expression pattern:
UP
Associated gene: cyclin D1
Associated microRNA: miR-195
Biological function: Promotes LSCC cell proliferation and G1/S cell cycle transition.
Molecular mechanism: Acts as a competing endogenous RNA (ceRNA) that sponges miR-195 to increase cyclin D1 expression.
Biological pathway or process:

proliferation (promotes); cell cycle (promotes); ceRNA regulation (promotes)

Detected method:
Q
Validation methods:

RT-qPCR; RNase R Treatment; Clinical Sample Validation; Transfection; MTT; Cell Cycle Assay; Luciferase Reporter Assay; Western Blot; Bioinformatics Analysis

Clinical significance:

High circMYLK expression was closely associated with advanced clinical stage (P=0.013) of LSCC patients.

Description:

circMYLK is up-regulated in LSCC tissues and cell lines and promotes LSCC cell proliferation by accelerating G1/S cell-cycle progression. Mechanistically, circMYLK functions as a ceRNA that sponges miR-195, thereby increasing cyclin D1 expression; miR-195 restoration counteracts circMYLK-driven oncogenic effects.

Confidence score:

0.7129

Other information
Title:

Circular RNA MYLK serves as an oncogene to promote cancer progression via microRNA-195/cyclin D1 axis in laryngeal squamous cell carcinoma.

Journal: Bioscience reports
Published: 2019
PubMed ID: 31427478
Study type:

combined biological and clinical study

Data availability: -
Code availability: -